Clinical trial
A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis
NCT00295282 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00295282 |
|---|---|
| Title | A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis |
| Official title | A Phase I, Multicenter, Dose-escalation Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Patients With Active Ulcerative Colitis |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | MDX-1100 (anti-CXCL10 human monoclonal antibody) |
| Enrollment | 24 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Feb 23, 2006 |
| Last update posted | Apr 23, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: